We couldn’t be more thrilled to have made a relatively last minute decision to attend the CannMed seminar at Harvard’s Med Campus this year. It was nothing short of a motivational mind-blow in terms of the scientific genius that is propelling this industry forward.
If there’s one thing that was all too apparent, it’s that the US really needs to take haste on embracing the benefits of cannabis at a national level to avoid being even later to the table.
Over the course of two days, renown scientists and respected doctors like Bonni Goldstein, Sean McAllister, and David Mieri showcased their research and case studies on everything from matching different strains’ extracts to different types of cancer, to the decentralization of cannabis genomics. In short, we are finally really starting to get to know this plant, even if today’s findings still only represent the tip of iceberg.
Above: Ph.D. David Mieri describes how variances in extracts, even within the same strain, can drastically impact efficacy when it comes to fighting cancerous cells.
Above: Deborah Kimless MD compares the amount of TCH potentially consumed by a recreational user to the micro-dose recommended for some medicinal patients in combination with other therapies.
Above: Mara Gordon compares the responses of breast cancer cells to pure extracted cannabinoids vs. whole-plant extracts.
Above: Sean McAllister discusses cannabinoids an anti-tumor agents as it relates to Id-1 expression and CBD-dependent anti-tumor pathways
Above: Orrin Devinsky MD details the anti-seizure effects of cannabis-based drug Epidiolex in patients with Dravet and Lennox-Gastaut Syndromes